Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 4, 2003
Last updated: February 6, 2009
Last verified: May 2007

RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of colorectal cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining celecoxib with leucovorin, fluorouracil, and oxaliplatin in treating patients who have metastatic colorectal cancer.

Condition Intervention Phase
Colorectal Cancer
Drug: celecoxib
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity [ Designated as safety issue: Yes ]
  • Time of disease control (progression-free survival) [ Designated as safety issue: No ]
  • Salvage surgery rate [ Designated as safety issue: No ]
  • Duration of chemotherapy-free intervals [ Designated as safety issue: No ]
  • Tolerability [ Designated as safety issue: Yes ]
  • Quality of life [ Designated as safety issue: No ]

Study Start Date: September 2003
Detailed Description:



  • Determine the response rate in patients with metastatic colorectal cancer treated with celecoxib, leucovorin calcium, fluorouracil, and oxaliplatin.


  • Determine the toxicity of this regimen in these patients.
  • Determine the time of disease control to evaluate progression-free survival in patients treated with this regimen.
  • Determine the salvage surgery rate in patients treated with this regimen.
  • Determine the duration of chemotherapy-free intervals in patients treated with this regimen.
  • Determine the tolerability of this regimen in these patients.
  • Determine the quality of life of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive FOLFOX7 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Patients also receive oral celecoxib twice daily beginning on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease stop treatment. If disease progression occurs during the chemotherapy-free interval, patients receive an additional 6 courses.

Patients with responding disease after receiving at least 6 courses of chemotherapy may undergo surgery. Beginning within 10 weeks after surgery, patients receive simplified LV5FU2 chemotherapy comprising leucovorin calcium IV over 2 hours on day 1, fluorouracil IV over 46 hours beginning on day 1, and oral celecoxib twice daily beginning on day 1. Treatment repeats every 14 days for at least 12 courses.

Quality of life is assessed at baseline, during courses 4 and 6, and then every 2 months thereafter.

Patients are followed at 1 month and then every 2 months thereafter.

PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the colon or rectum

    • Metastatic disease
    • Inoperable disease (i.e., not suitable for complete carcinological surgical resection)
  • Measurable disease or nonmeasurable disease

    • At least 1 unidimensionally measurable lesion at least 20 mm by conventional CT scan OR 10 mm by spiral CT scan
    • Nonmeasurable disease defined as all other lesions, including small lesions or truly nonmeasurable disease
  • No CNS metastases
  • No exclusive bone metastases
  • No symptomatic ascites or pleural effusion not evacuated before study entry



  • 18 to 75

Performance status

  • WHO 0-2

Life expectancy

  • Not specified


  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • No known significant bleeding disorder


  • Alkaline phosphatase less than 3 times upper limit of normal (ULN)


  • Creatinine less than 1.5 times ULN OR
  • Creatinine clearance at least 30 mL/min
  • No uncontrolled hypercalcemia


  • No congestive heart failure


  • No total or partial bowel obstruction
  • No active gastric or duodenal ulceration or gastrointestinal bleeding within the past year
  • No active inflammatory bowel disease


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • HIV negative
  • No peripheral sensory neuropathy
  • No known sensitivity to celecoxib, other COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides
  • No AIDS-related illness
  • No active infection
  • No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
  • No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation


Biologic therapy

  • No prior immunotherapy for metastatic disease


  • Prior adjuvant chemotherapy allowed provided the progression-free interval after completion of therapy is more than 6 months in duration
  • No prior chemotherapy for metastatic disease
  • No prior adjuvant oxaliplatin
  • No other concurrent chemotherapy

Endocrine therapy

  • No concurrent chronic oral or IV corticosteroid use (i.e., 2 weeks or longer in duration)


  • No concurrent radiotherapy


  • Not specified


  • More than 30 days since prior investigational drugs
  • No other concurrent investigational drugs or treatments
  • No concurrent prophylactic fluconazole
  • No concurrent chronic full-dose aspirin (at least 325 mg/day), other nonsteroidal anti-inflammatory drugs (NSAIDs), or other cyclooxygenase (COX)-2 inhibitors

    • Concurrent low-dose (cardioprotective) aspirin (80 mg/day or equivalent) allowed
  • No concurrent lithium
  • No other concurrent anticancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00072553

Hopital Tenon
Paris, France, 75970
Sponsors and Collaborators
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Study Chair: Thierry Andre, MD Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
  More Information

Additional Information:
Publications: Identifier: NCT00072553     History of Changes
Other Study ID Numbers: CDR0000340181, GERCOR-OPTIMOX2-CELECOXIB-2002, EU-20325
Study First Received: November 4, 2003
Last Updated: February 6, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV rectal cancer
stage IV colon cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum
recurrent rectal cancer
recurrent colon cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents processed this record on November 27, 2014